WO2021248764A1 - Method for preparing laninamivir octanoate intermediate by means of one-pot synthesis - Google Patents

Method for preparing laninamivir octanoate intermediate by means of one-pot synthesis Download PDF

Info

Publication number
WO2021248764A1
WO2021248764A1 PCT/CN2020/120751 CN2020120751W WO2021248764A1 WO 2021248764 A1 WO2021248764 A1 WO 2021248764A1 CN 2020120751 W CN2020120751 W CN 2020120751W WO 2021248764 A1 WO2021248764 A1 WO 2021248764A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
formula
reaction
compound represented
nah
Prior art date
Application number
PCT/CN2020/120751
Other languages
French (fr)
Chinese (zh)
Inventor
袁建栋
黄仰青
池建文
顾家宁
杭文明
林祥义
孙鹏
Original Assignee
博瑞生物医药(苏州)股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 博瑞生物医药(苏州)股份有限公司 filed Critical 博瑞生物医药(苏州)股份有限公司
Publication of WO2021248764A1 publication Critical patent/WO2021248764A1/en

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Definitions

  • the invention relates to the technical field of drug synthesis, in particular to a one-pot method for preparing an intermediate of lanimivir octoate.
  • Laninamivir caprylate is a neuraminidase inhibitor developed by Biota Pharmaceuticals and Daiichi Sankyo. It can be used to treat influenza virus infections that are resistant to oseltamivir (Tamiflu). In 2010, it was approved to be marketed in Japan under the name Inavir.
  • Lanimivir caprylate has good effects on H1N1, H5N1, N9 and influenza B viruses and Tamiflu-resistant viruses. Up to now, lanimivir caprylate has not been listed in the country, and there is no registered manufacturer. In order to guide the R&D and production of generic drugs and improve the availability of drugs to the public, the Center for Drug Evaluation of the State Food and Drug Administration organized a screening of foreign drugs that have expired, terminated, or become invalid and have no generic applications. Lanimivir caprylate was initially screened and included in the "List of the First Batch of Drugs with Expiration, Termination, and Invalidation without Generic Application".
  • Patent CN101679339A discloses the synthesis of lanimivir octoate by 11-step reaction with sialic acid as the starting material.
  • the synthesis route is as follows:
  • This route uses commercially supplied sialic acid as the starting material to synthesize lanimivir octoate through an 11-step reaction.
  • the unit reaction effect is good and the overall yield is high.
  • Patent CN103435582A discloses the synthesis of lanimivir octoate via a 5-step reaction with zanamivir as the starting material.
  • the synthesis route is as follows:
  • Method 3 Ma Dawei's research group used D-isoascorbic acid as the starting material, followed by a series of oxidation, reduction, protection, deprotection and other reactions to synthesize lanimivir octoate.
  • the synthetic route is as follows:
  • the synthesis route is relatively novel, the unit reaction yield is moderate, but the market supply of starting materials and catalyst ligands is small, the price is expensive, and it is not suitable for scale-up production.
  • the chiral purity of intermediate S-3 and intermediate S-8 is not high. , Resulting in more impurities in subsequent isomers, and the quality of the final product is difficult to control.
  • the purpose of the present invention is to provide a one-pot method for preparing lanimivir octoate intermediates.
  • a one-pot method for preparing lanimivir octoate intermediates adopts a synthetic method including the following:
  • R 1 is a benzyl group, a substituted benzyl group, or an allyl group.
  • the aforementioned substituted benzyl group means that the benzene ring on the benzyl group is mono- or multiple-substituted by groups such as chlorine, bromine, iodine, nitro, alkoxy, alkyl, and aromatic.
  • the above-mentioned one-pot method for preparing lanimivir octoate intermediate includes the following steps: mixing and stirring the compound represented by formula (4) with an organic solvent and R 1 OH, and then adding NaH and stirring for 30-60 min under the protection of nitrogen. Then (R 1 O) 2 CO is added, and the reaction is stirred at 0-80° C. for 30 min-24 h, and then separated to obtain the compound represented by formula (5).
  • the crude compound of formula (5) is crystallized by toluene or methanol to obtain crystals of the compound represented by formula (5).
  • the reaction temperature is 10-60°C.
  • reaction temperature is 50-55°C.
  • the reaction time is 30 minutes to 5 hours.
  • the organic solvent is any one or more of toluene, N,N-dimethylformamide, benzyl alcohol, n-heptane, methyl tert-butyl ether, tetrahydrofuran, and 1,4-dioxane.
  • the mass concentration of the NaH is 60%.
  • R 1 is benzyl
  • the mass ratio of the compound represented by formula (4), R 1 OH, NaH, and (R 1 O) 2 CO is 8-12:15-30:0.02-0.1:12-36.
  • the mass ratio of the compound represented by formula (4), R 1 OH, NaH, and (R 1 O) 2 CO is 9.8:20:0.04:24.22.
  • R 1 is benzyl, substituted benzyl or allyl
  • X is Cl -, Br -, I - , MeSO 4 -, TfO -.
  • Step 1 In the presence of a base, the compound represented by formula (1) reacts with R 1 X to produce the compound represented by formula (2).
  • the base is not particularly limited, as long as it can be neutralized with a carboxylic acid, and it may be an organic base or an inorganic base.
  • the organic base such as triethylamine, diisopropylethylamine, N,N-dimethyl-4-aminopyridine or pyridine
  • inorganic base such as cesium carbonate, potassium carbonate, sodium carbonate, sodium hydroxide or Potassium hydroxide.
  • An inorganic base is preferable, and cesium carbonate or potassium carbonate is more preferable.
  • Step 2 In the presence of an organic base, the compound represented by formula (2) reacts with acetic anhydride to produce the compound represented by formula (3). There is no restriction on the organic base, as long as it can be neutralized with carboxylic acid.
  • the organic base is any one or more of triethylamine, diisopropylethylamine, N,N-dimethyl-4-aminopyridine, and pyridine.
  • the reaction temperature in step 2 is -30°C to 100°C. Preferably it is 0-35 degreeC.
  • the reaction time of step 2 is 30min-24h. Preferably it is 10-15h.
  • Step 3 The compound represented by the formula (3) is catalyzed by trimethylsilyl trifluoromethanesulfonate to produce the compound represented by the formula (4).
  • the reaction temperature in step 3 is 0 to 70°C. Preferably it is 30 degreeC-60 degreeC.
  • the reaction time of step 3 is 1.0h-24h. Preferably it is 1.0-3.0h.
  • a preparation method of lanimivir octoate (compound of formula I) adopts a synthetic method including the following:
  • Step 5 is to react the compound represented by formula (5) with dimethyl sulfate or methyl iodide in the presence of a base to produce the compound represented by formula (6).
  • the reaction temperature in step 5 is 0-70°C, preferably 0-30°C.
  • Step 5 The reaction time is 30 minutes to 24 hours, preferably 1.0 to 15 hours.
  • Step 6 is to react the compound represented by formula (6) with azide trimethylsilane under the catalysis of titanium isopropoxide to produce the compound represented by formula (7).
  • Step 6 The reaction temperature is 0 to 120°C, preferably 0 to 40°C.
  • Step 6 The reaction time is 3.0 to 48 hours, preferably 3.0 to 24 hours.
  • Step 7 is the reaction of the compound represented by formula (7) with triphenylphosphine to produce the compound represented by formula (8).
  • the reaction temperature in step 7 is -10 to 80°C, preferably 0 to 60°C.
  • Step 7 The reaction time is 10 minutes to 48 hours, preferably 10 minutes to 5 hours.
  • Step 8 is the reaction of the compound represented by formula (8) with a base to produce the compound represented by formula (9).
  • inorganic bases are preferred, and lithium hydroxide, sodium hydroxide, and potassium hydroxide are more preferred.
  • the reaction temperature in step 8 is preferably -10 to 100°C, more preferably 0 to 50°C.
  • Step 8 The reaction time is preferably 10 minutes to 48 hours, more preferably 0.5 hours to 6 hours.
  • Step 9 is the reaction of the compound represented by formula (9) with the compound represented by formula (10) to produce the compound represented by formula (11).
  • the step 9 reaction solvent is preferably purified water.
  • the reaction temperature in Step 9 is 0-100°C, and preferably 5-50°C.
  • Step 9 The reaction time is 24h to 72h, and preferably 24 to 60h.
  • Step 10 is the reaction of the compound represented by formula (11) in the presence of trifluoroacetic acid to produce the compound represented by formula (12).
  • the reaction temperature in step 10 is -20 to 100°C, and preferably 0 to 45°C.
  • the reaction time of step 10 is 0.5 to 24 hours, and preferably 0.5 to 8 hours.
  • Step 11 is to react the compound represented by formula (12) with compound 13 or compound 14 in the presence of an acid, and then react with water to produce the compound represented by formula (I) or a pharmacologically acceptable salt thereof.
  • the acid in step 11 is preferably an inorganic acid, and more preferably hydrochloric acid.
  • the reaction temperature in step 11 is preferably -10 to 70°C, and preferably 0 to 50°C.
  • the step 11 reaction time is preferably 10 minutes to 24 hours, and more preferably 10 minutes to 5 hours.
  • Compound 13 and compound 14 can be prepared by the preparation methods in the prior art; they can also be prepared by the following route:
  • the present invention innovatively adopts a one-pot method to synthesize lanimivir octoate intermediate compound (5) from compound (4).
  • the reaction is mild and fast, and the product does not require column chromatography, and simple post-treatment can proceed to the next reaction, saving energy Consumption, pollution reduction, simple operation, low cost, suitable for industrial production.
  • the lanimivir octoate intermediate compound (5) prepared by the one-pot method in the present invention has a yield of more than 87%, and the yield of lanimivir octoate prepared by using the intermediate is more than 85%.
  • the product of the CN101679339A method has many impurities and requires column chromatography, and the yield of the two-step method is only 76.9%.
  • Figure 1 is a hydrogen spectrum of compound (2)
  • Figure 2 is a hydrogen spectrum of compound (3)
  • Figure 3 is a hydrogen spectrum of compound (4)
  • Figure 4 is a hydrogen spectrum of compound (5)
  • Figure 5 is a hydrogen spectrum of compound (6)
  • Figure 6 is a hydrogen spectrum of compound (12).
  • Figure 7 is a hydrogen spectrum of compound (13).
  • the one-pot method for preparing the lanimivir caprylate intermediate of the present invention adopts the following synthetic methods:
  • R 1 is a benzyl group, a substituted benzyl group, or an allyl group.
  • the aforementioned substituted benzyl group means that the benzene ring on the benzyl group is mono- or multiple-substituted by groups such as chlorine, bromine, iodine, nitro, alkoxy, alkyl, and aromatic.
  • the above-mentioned one-pot method for preparing lanimivir octoate intermediate includes the following steps: mixing and stirring the compound represented by formula (4) with an organic solvent and R 1 OH, and then adding NaH and stirring for 30-60 min under the protection of nitrogen. Then (R 1 O) 2 CO is added, and the reaction is stirred at 0-80° C. for 30 min-24 h, and then separated to obtain the compound represented by formula (5).
  • the crude compound of formula (5) is crystallized by toluene or methanol to obtain crystals of the compound represented by formula (5).
  • the reaction temperature is 10-60°C.
  • reaction temperature is 50-55°C.
  • the reaction time is 30 minutes to 5 hours.
  • the organic solvent is any one or more of toluene, N,N-dimethylformamide, benzyl alcohol, n-heptane, methyl tert-butyl ether, tetrahydrofuran, and 1,4-dioxane.
  • the mass concentration of the NaH is 60%.
  • R 1 is benzyl
  • the mass ratio of the compound represented by formula (4), R 1 OH, NaH, and (R 1 O) 2 CO is 8-12:15-30:0.02-0.1:12-36.
  • the mass ratio of the compound represented by formula (4), R 1 OH, NaH, and (R 1 O) 2 CO is 9.8:20:0.04:24.22.
  • R 1 is benzyl, substituted benzyl or allyl
  • X is Cl -, Br -, I - , MeSO 4 -, TfO -.
  • Step 1 In the presence of a base, the compound represented by formula (1) reacts with R 1 X to produce the compound represented by formula (2).
  • the base is not particularly limited, as long as it can be neutralized with a carboxylic acid, and it may be an organic base or an inorganic base.
  • the organic base such as triethylamine, diisopropylethylamine, N,N-dimethyl-4-aminopyridine or pyridine
  • inorganic base such as cesium carbonate, potassium carbonate, sodium carbonate, sodium hydroxide, Potassium hydroxide.
  • An inorganic base is preferable, and cesium carbonate or potassium carbonate is more preferable.
  • Step 2 In the presence of an organic base, the compound represented by formula (2) reacts with acetic anhydride to produce the compound represented by formula (3). There is no restriction on the organic base, as long as it can be neutralized with a carboxylic acid.
  • the organic base is any one or more of triethylamine, diisopropylethylamine, N,N-dimethyl-4-aminopyridine, and pyridine.
  • the reaction temperature in step 2 is -30°C to 100°C. Preferably it is 0-35 degreeC.
  • the reaction time of step 2 is 30min-24h. Preferably it is 10-15h.
  • Step 3 The compound represented by formula (3) is catalyzed by trimethylsilyl trifluoromethanesulfonate to produce the compound represented by formula (4).
  • the reaction temperature in step 3 is 0 to 70°C. Preferably it is 30 degreeC-60 degreeC.
  • the reaction time of step 3 is 1.0h-24h. Preferably it is 1.0-3.0h.
  • the preparation method of lanimivir octoate (compound of formula I) of the present invention adopts a synthetic method including the following:
  • Step 5 is to react the compound represented by formula (5) with dimethyl sulfate or methyl iodide in the presence of a base to produce the compound represented by formula (6).
  • the reaction temperature in step 5 is 0-70°C, preferably 0-30°C.
  • Step 5 The reaction time is 30 minutes to 24 hours, preferably 1.0 to 15 hours.
  • Step 6 is to react the compound represented by formula (6) with azidotrimethylsilane under the catalysis of titanium isopropoxide to produce the compound represented by formula (7).
  • Step 6 The reaction temperature is 0 to 120°C, preferably 0 to 40°C.
  • Step 6 The reaction time is 3.0 to 48 hours, preferably 3.0 to 24 hours.
  • Step 7 is the reaction of the compound represented by formula (7) with triphenylphosphine to produce the compound represented by formula (8).
  • the reaction temperature in step 7 is -10 to 80°C, preferably 0 to 60°C.
  • Step 7 The reaction time is 10 minutes to 48 hours, preferably 10 minutes to 5 hours.
  • Step 8 is the reaction of the compound represented by formula (8) with a base to produce the compound represented by formula (9).
  • inorganic bases are preferred, and lithium hydroxide, sodium hydroxide, and potassium hydroxide are more preferred.
  • the reaction temperature in step 8 is preferably -10 to 100°C, more preferably 0 to 50°C.
  • Step 8 The reaction time is preferably 10 minutes to 48 hours, more preferably 0.5 hours to 6 hours.
  • Step 9 is the reaction of the compound represented by formula (9) with the compound represented by formula (10) to produce the compound represented by formula (11).
  • the step 9 reaction solvent is preferably purified water.
  • the reaction temperature in Step 9 is 0-100°C, and preferably 5-50°C.
  • Step 9 The reaction time is 24h to 72h, and preferably 24 to 60h.
  • Step 10 is the reaction of the compound represented by formula (11) in the presence of trifluoroacetic acid to produce the compound represented by formula (12).
  • the reaction temperature in step 10 is -20 to 100°C, and preferably 0 to 45°C.
  • the reaction time of step 10 is 0.5 to 24 hours, and preferably 0.5 to 8 hours.
  • Step 11 is to react the compound represented by formula (12) with compound 13 or compound 14 in the presence of an acid, and then react with water to produce the compound represented by formula (I) or a pharmacologically acceptable salt thereof.
  • the acid in step 11 is preferably an inorganic acid, and more preferably hydrochloric acid.
  • the reaction temperature in step 11 is preferably -10 to 70°C, and preferably 0 to 50°C.
  • the step 11 reaction time is preferably 10 minutes to 24 hours, and more preferably 10 minutes to 5 hours.
  • Compound 13 and compound 14 can be prepared by the preparation methods in the prior art; they can also be prepared by the following route:
  • the preparation of compound (2) includes the following steps:
  • N-acetylneuraminic acid compound 1
  • Cs 2 CO 3 16.30g, 125ml DMF compound 2
  • BrBn 26.70g compound 2
  • 500ml reaction flask 500ml reaction flask
  • To dryness add 300ml isopropanol, heat to 70°C, heat to filter out the insoluble matter, stir the filtrate at room temperature for 3-4h, filter, rinse the filter cake with isopropanol, dry the filter cake under reduced pressure to obtain compound (2) White powder 18.50g, yield 46.25%.
  • the hydrogen spectrum of compound (2) is shown in Figure 1.
  • the temperature in the preparation process of compound (2), after adding 300 ml of isopropanol, the temperature can be increased to 80°C or 75°C, and then the insoluble matter can be filtered out by hot filtration.
  • the preparation of compound (3) includes the following steps:
  • the preparation of compound (4) includes the following steps:
  • the reaction was stirred at 55° C. for 2 h.
  • the stirring reaction temperature can also be 10°C, 52°C, 60°C, or 80°C.
  • the stirring reaction time can be adjusted within 30min-24h. Changing the above reaction temperature or time, the yield of compound (5) is basically the same as that of Example 4.
  • the toluene solvent can also be replaced with N,N-dimethylformamide, benzyl alcohol, n-heptane, methyl tert-butyl ether, tetrahydrofuran, 1,4-di Any one or more of oxane.
  • the mass ratio of the compound represented by formula (4), R 1 OH, NaH, and (R 1 O) 2 CO is 12:15:0.1:12.
  • R1 can also be benzyl substituted by chlorine, bromine, iodine, nitro, alkoxy, alkyl or aromatic; even R1 can also be allyl.
  • the preparation of compound (9) includes the following steps:
  • the preparation of compound (11) includes the following steps:
  • the preparation of compound (12) includes the following steps:
  • the hydrogen spectrum of compound (12) is shown in Fig. 7.
  • Compound 13 in this example can be replaced with compound 14, and other conditions remain unchanged.
  • This comparative example is different from Example 4 only in that dibenzyl carbonate is replaced with carbonyl diimidazole.
  • the product has many impurities and requires column chromatography, and the final yield of compound (5) is only 20%.
  • This comparative example is different from Example 4 only in that dibenzyl carbonate is replaced with benzyl chloroformate. There are many impurities and column chromatography is required. The final yield of compound (5) is only 25%.

Abstract

The present invention relates to the technical field of medicine synthesis, and specifically relates to a method for preparing a laninamivir octanoate intermediate by means of one-pot synthesis. The method for preparing a laninamivir octanoate intermediate by means of one-pot synthesis comprises: subjecting a compound as represented by formula (4) to a reaction in the presence of R1OH, NaH and (R1O)2CO to obtain a compound as represented by formula (5), wherein R1 is benzyl, substituted benzyl, or allyl. A laninamivir octanoate intermediate compound (5) is innovatively synthesized from a compound (4) by means of using one-pot synthesis; the reaction is gentle and rapid, and the next-step reaction can be carried out after simple post-treatment; energy consumption is saved, the pollution is reduced, operation is simple and the cost is low, such that the method is suitable for industrial production. The laninamivir octanoate intermediate compound (5) prepared by means of using one-pot synthesis has a yield of at least 87%.

Description

一种一锅法制备辛酸拉尼米韦中间体的方法One-pot method for preparing lanimivir caprylate intermediate 技术领域Technical field
本发明涉及药物合成技术领域,具体涉及一种一锅法制备辛酸拉尼米韦中间体的方法。The invention relates to the technical field of drug synthesis, in particular to a one-pot method for preparing an intermediate of lanimivir octoate.
背景技术Background technique
辛酸拉尼米韦(Laninamivir)是Biota Pharmaceuticals和Daiichi Sankyo公司研发的一种神经氨酸酶抑制剂,可用于治疗对奥司他韦(达菲)具有抗药性的流感病毒感染。于2010年获得批准以Inavir名称在日本上市。Laninamivir caprylate is a neuraminidase inhibitor developed by Biota Pharmaceuticals and Daiichi Sankyo. It can be used to treat influenza virus infections that are resistant to oseltamivir (Tamiflu). In 2010, it was approved to be marketed in Japan under the name Inavir.
辛酸拉尼米韦化学结构式如下:The chemical structural formula of lanimivir caprylate is as follows:
Figure PCTCN2020120751-appb-000001
Figure PCTCN2020120751-appb-000001
辛酸拉尼米韦对H1N1、H5N1、N9和B型流感病毒以及对达菲耐药病毒均有较好的效果,截至目前,辛酸拉尼米韦在国内未上市,也没有注册申报厂家。为引导仿制药研发生产,提高公众用药可及性,国家食品药品监督管理总局药品审评中心组织对国内化合物专利权到期、终止、无效且尚无仿制申请的国外已上市药品进行筛选,其中辛酸拉尼米韦初步筛选并纳入《首批专利权到期、终止、无效尚且无仿制申请的药品清单》。Lanimivir caprylate has good effects on H1N1, H5N1, N9 and influenza B viruses and Tamiflu-resistant viruses. Up to now, lanimivir caprylate has not been listed in the country, and there is no registered manufacturer. In order to guide the R&D and production of generic drugs and improve the availability of drugs to the public, the Center for Drug Evaluation of the State Food and Drug Administration organized a screening of foreign drugs that have expired, terminated, or become invalid and have no generic applications. Lanimivir caprylate was initially screened and included in the "List of the First Batch of Drugs with Expiration, Termination, and Invalidation without Generic Application".
目前,辛酸拉尼米韦的制备方法归结为如下三种方法:At present, the preparation method of lanimivir caprylate is summarized into the following three methods:
方法一,专利CN101679339A公开了以唾液酸为起始物料经11步反应合成辛酸拉尼米韦,合成路线如下所示:Method 1: Patent CN101679339A discloses the synthesis of lanimivir octoate by 11-step reaction with sialic acid as the starting material. The synthesis route is as follows:
Figure PCTCN2020120751-appb-000002
Figure PCTCN2020120751-appb-000002
Figure PCTCN2020120751-appb-000003
Figure PCTCN2020120751-appb-000003
该路线以商业化供应的唾液酸为起始物料,经11步反应合成辛酸拉尼米韦,其单元反应效果好,整体收率高。This route uses commercially supplied sialic acid as the starting material to synthesize lanimivir octoate through an 11-step reaction. The unit reaction effect is good and the overall yield is high.
方法二,专利CN103435582A公开了以扎那米韦为起始物料经5步反应合成辛酸拉尼米韦,合成路线如下所示:Method 2: Patent CN103435582A discloses the synthesis of lanimivir octoate via a 5-step reaction with zanamivir as the starting material. The synthesis route is as follows:
Figure PCTCN2020120751-appb-000004
Figure PCTCN2020120751-appb-000004
该方法虽然步骤少,但是以扎纳米韦为起始原料,原料的价格过于昂贵,难以满足仿制药的需求;Although this method has few steps, it uses zanamivir as the starting material, and the price of the raw material is too expensive to meet the demand for generic drugs;
方法三,马大伟课题组以D-异抗坏血酸为起始物料,经手性催化关环,再经一系列氧化、还原、保护、脱保护等反应合成辛酸拉尼米韦,合成路线如下所示:Method 3, Ma Dawei's research group used D-isoascorbic acid as the starting material, followed by a series of oxidation, reduction, protection, deprotection and other reactions to synthesize lanimivir octoate. The synthetic route is as follows:
Figure PCTCN2020120751-appb-000005
Figure PCTCN2020120751-appb-000005
该合成路线比较新颖,单元反应收率适中,但起始物料及催化剂配体市场供应较少,价格昂贵,不适合放大生产,同时中间体S-3和中间体S-8手性纯度不高,导致后续异构体杂质较多,最终产品质量难以控制。The synthesis route is relatively novel, the unit reaction yield is moderate, but the market supply of starting materials and catalyst ligands is small, the price is expensive, and it is not suitable for scale-up production. At the same time, the chiral purity of intermediate S-3 and intermediate S-8 is not high. , Resulting in more impurities in subsequent isomers, and the quality of the final product is difficult to control.
以上三条路线,由于路线二的原料价格过于昂贵,路线三的试剂过于昂贵,均不适合工业化生产,因此,我们的研究集中在对专利CN101679339A的工艺优化上,我们在重复CN101679339A的工艺中发现专利中生产化合物3的过程中需要添加浓硫酸,反应条件比较苛刻,工业化生产中危险性较高;化合物4-6生产过程中反应步骤繁琐且需要柱层析,难以满足工业化生产需求,需要进一步的优化。For the above three routes, because the raw materials of route 2 are too expensive and the reagents of route 3 are too expensive, they are not suitable for industrial production. Therefore, our research focuses on the process optimization of patent CN101679339A. We found patents in the process of repeating CN101679339A. In the process of producing compound 3, it is necessary to add concentrated sulfuric acid, the reaction conditions are relatively harsh, and the risk is high in industrial production; the reaction steps in the production process of compound 4-6 are cumbersome and require column chromatography, which is difficult to meet the requirements of industrial production, and further optimization.
发明内容Summary of the invention
本发明的目的在于提供一种一锅法制备辛酸拉尼米韦中间体的方法。The purpose of the present invention is to provide a one-pot method for preparing lanimivir octoate intermediates.
为实现上述目的,本发明的技术方案是:In order to achieve the above objective, the technical solution of the present invention is:
一种一锅法制备辛酸拉尼米韦中间体的方法,采用包括如下的合成方法:A one-pot method for preparing lanimivir octoate intermediates adopts a synthetic method including the following:
Figure PCTCN2020120751-appb-000006
Figure PCTCN2020120751-appb-000006
其中,R 1为苄基、取代苄基或烯丙基。 Wherein, R 1 is a benzyl group, a substituted benzyl group, or an allyl group.
上述取代苄基,指:苄基上的苯环被氯、溴、碘、硝基、烷氧基、烷基、芳香基等基团单取代或多取代。The aforementioned substituted benzyl group means that the benzene ring on the benzyl group is mono- or multiple-substituted by groups such as chlorine, bromine, iodine, nitro, alkoxy, alkyl, and aromatic.
上述一锅法制备辛酸拉尼米韦中间体的方法,包括以下步骤:将式(4)所示化合物与有机溶剂、R 1OH混合搅拌,之后在氮气保护下,加入NaH搅拌30~60min,然后加入(R 1O) 2CO,于0~80℃搅拌反应30min~24h,之后分离,得式(5)所示化合物。 The above-mentioned one-pot method for preparing lanimivir octoate intermediate includes the following steps: mixing and stirring the compound represented by formula (4) with an organic solvent and R 1 OH, and then adding NaH and stirring for 30-60 min under the protection of nitrogen. Then (R 1 O) 2 CO is added, and the reaction is stirred at 0-80° C. for 30 min-24 h, and then separated to obtain the compound represented by formula (5).
式(5)化合物粗品经甲苯或甲醇结晶,可得式(5)表示化合物的晶体。The crude compound of formula (5) is crystallized by toluene or methanol to obtain crystals of the compound represented by formula (5).
优选的,所述反应温度为10~60℃。Preferably, the reaction temperature is 10-60°C.
进一步优选的,所述反应温度为50~55℃。More preferably, the reaction temperature is 50-55°C.
优选的,所述反应时间为30min~5h。Preferably, the reaction time is 30 minutes to 5 hours.
所述有机溶剂为甲苯、N,N-二甲基甲酰胺、苯甲醇、正庚烷、甲基叔丁基醚、四氢呋喃、1,4-二氧六环中的任意一种或几种。The organic solvent is any one or more of toluene, N,N-dimethylformamide, benzyl alcohol, n-heptane, methyl tert-butyl ether, tetrahydrofuran, and 1,4-dioxane.
所述NaH的质量浓度为60%。The mass concentration of the NaH is 60%.
优选的,R 1为苄基。 Preferably, R 1 is benzyl.
上述方法中,式(4)所示化合物、R 1OH、NaH、(R 1O) 2CO的质量比为8-12:15-30:0.02-0.1:12-36。优选地,式(4)所示化合物、R 1OH、NaH、(R 1O) 2CO的质量比为9.8:20:0.04:24.22。 In the above method, the mass ratio of the compound represented by formula (4), R 1 OH, NaH, and (R 1 O) 2 CO is 8-12:15-30:0.02-0.1:12-36. Preferably, the mass ratio of the compound represented by formula (4), R 1 OH, NaH, and (R 1 O) 2 CO is 9.8:20:0.04:24.22.
上述式(4)所示化合物由以下路线合成:The compound represented by the above formula (4) is synthesized by the following route:
Figure PCTCN2020120751-appb-000007
Figure PCTCN2020120751-appb-000007
其中,R 1为苄基、取代苄基或烯丙基,X为Cl -、Br -、I -、MeSO 4 -、TfO -Wherein, R 1 is benzyl, substituted benzyl or allyl, X is Cl -, Br -, I - , MeSO 4 -, TfO -.
步骤1,在碱存在下,式(1)所示的化合物与R 1X反应生成式(2)表示的化合物。 Step 1. In the presence of a base, the compound represented by formula (1) reacts with R 1 X to produce the compound represented by formula (2).
所述碱没有特别的限制,可以与羧酸中和即可,可以是有机碱或无机碱。The base is not particularly limited, as long as it can be neutralized with a carboxylic acid, and it may be an organic base or an inorganic base.
优选的,所述有机碱诸如三乙胺、二异丙基乙胺、N,N-二甲基-4-氨基吡啶或吡啶;无机碱诸如碳酸铯、碳酸钾、碳酸钠、氢氧化钠或氢氧化钾。Preferably, the organic base such as triethylamine, diisopropylethylamine, N,N-dimethyl-4-aminopyridine or pyridine; inorganic base such as cesium carbonate, potassium carbonate, sodium carbonate, sodium hydroxide or Potassium hydroxide.
优选无机碱,且进一步优选碳酸铯或碳酸钾。An inorganic base is preferable, and cesium carbonate or potassium carbonate is more preferable.
步骤2,在有机碱存在下,式(2)表示的化合物与乙酸酐反应,生成式(3)表示的化合物。关于有机碱没有限制,可以与羧酸中和即可。Step 2. In the presence of an organic base, the compound represented by formula (2) reacts with acetic anhydride to produce the compound represented by formula (3). There is no restriction on the organic base, as long as it can be neutralized with carboxylic acid.
优选的,所述有机碱为三乙胺、二异丙基乙胺、N,N-二甲基-4-氨基吡啶、吡啶中的任意一种或几种。Preferably, the organic base is any one or more of triethylamine, diisopropylethylamine, N,N-dimethyl-4-aminopyridine, and pyridine.
步骤2的反应温度为-30℃~100℃。优选为0~35℃。The reaction temperature in step 2 is -30°C to 100°C. Preferably it is 0-35 degreeC.
步骤2的反应时间是30min~24h。优选为10~15h。The reaction time of step 2 is 30min-24h. Preferably it is 10-15h.
步骤3,式(3)表示的化合物在三氟甲磺酸三甲硅酯催化下,产生式(4)表示的化合物。Step 3. The compound represented by the formula (3) is catalyzed by trimethylsilyl trifluoromethanesulfonate to produce the compound represented by the formula (4).
步骤3的反应温度0~70℃。优选为30℃~60℃。The reaction temperature in step 3 is 0 to 70°C. Preferably it is 30 degreeC-60 degreeC.
步骤3的反应时间是1.0h~24h。优选为1.0~3.0h。The reaction time of step 3 is 1.0h-24h. Preferably it is 1.0-3.0h.
步骤3后处理滴加三乙胺淬灭反应。After step 3, triethylamine was added dropwise to quench the reaction.
一种辛酸拉尼米韦(式Ⅰ化合物)的制备方法,采用包括如下的合成方法:A preparation method of lanimivir octoate (compound of formula I) adopts a synthetic method including the following:
Figure PCTCN2020120751-appb-000008
Figure PCTCN2020120751-appb-000008
步骤5是在碱存在下,式(5)表示的化合物与硫酸二甲酯或碘甲烷反应,产生式(6) 表示的化合物。Step 5 is to react the compound represented by formula (5) with dimethyl sulfate or methyl iodide in the presence of a base to produce the compound represented by formula (6).
步骤5反应温度为0-70℃,优选0-30℃。The reaction temperature in step 5 is 0-70°C, preferably 0-30°C.
步骤5反应时间为30min~24h,优选1.0~15h。Step 5: The reaction time is 30 minutes to 24 hours, preferably 1.0 to 15 hours.
步骤6是在异丙醇钛催化下使式(6)表示的化合物与叠氮三甲基硅烷反应,以产生式(7)表示的化合物。Step 6 is to react the compound represented by formula (6) with azide trimethylsilane under the catalysis of titanium isopropoxide to produce the compound represented by formula (7).
步骤6反应温度为0~120℃,优选为0~40℃。Step 6: The reaction temperature is 0 to 120°C, preferably 0 to 40°C.
步骤6反应时间为3.0~48h,优选3.0~24h。Step 6: The reaction time is 3.0 to 48 hours, preferably 3.0 to 24 hours.
步骤7是式(7)表示的化合物与三苯基膦反应以产生式(8)表示的化合物。Step 7 is the reaction of the compound represented by formula (7) with triphenylphosphine to produce the compound represented by formula (8).
步骤7反应温度为-10~80℃,优选0~60℃。The reaction temperature in step 7 is -10 to 80°C, preferably 0 to 60°C.
步骤7反应时间为10分钟~48h,优选10min~5h。Step 7: The reaction time is 10 minutes to 48 hours, preferably 10 minutes to 5 hours.
步骤8是式(8)表示的化合物与碱反应以产生式(9)表示的化合物。Step 8 is the reaction of the compound represented by formula (8) with a base to produce the compound represented by formula (9).
关于碱,优选无机碱,且更优选氢氧化锂、氢氧化钠、氢氧化钾。Regarding the base, inorganic bases are preferred, and lithium hydroxide, sodium hydroxide, and potassium hydroxide are more preferred.
步骤8反应温度优选-10~100℃,进一步优选0~50℃。The reaction temperature in step 8 is preferably -10 to 100°C, more preferably 0 to 50°C.
步骤8反应时间优选10分钟~48h,进一步优选0.5h~6h。Step 8: The reaction time is preferably 10 minutes to 48 hours, more preferably 0.5 hours to 6 hours.
步骤9是式(9)表示的化合物与式(10)表示的化合物反应以产生式(11)表示的化合物。Step 9 is the reaction of the compound represented by formula (9) with the compound represented by formula (10) to produce the compound represented by formula (11).
步骤9反应溶剂优选纯化水。The step 9 reaction solvent is preferably purified water.
步骤9反应温度是0-100℃,且优选5~50℃。The reaction temperature in Step 9 is 0-100°C, and preferably 5-50°C.
步骤9反应时间是24h~72h,且优选24~60h。Step 9: The reaction time is 24h to 72h, and preferably 24 to 60h.
步骤10是式(11)表示的化合物在三氟乙酸存在下反应,以产生式(12)表示的化合物。Step 10 is the reaction of the compound represented by formula (11) in the presence of trifluoroacetic acid to produce the compound represented by formula (12).
步骤10反应温度是-20~100℃,且优选0~45℃。The reaction temperature in step 10 is -20 to 100°C, and preferably 0 to 45°C.
步骤10反应时间是0.5h~24h,且优选0.5~8h。The reaction time of step 10 is 0.5 to 24 hours, and preferably 0.5 to 8 hours.
步骤11是在酸存在下使式(12)表示的化合物与化合物13或化合物14反应,之后再与水反应,以产生由式(Ⅰ)表示的化合物或其药理学可接受的盐。Step 11 is to react the compound represented by formula (12) with compound 13 or compound 14 in the presence of an acid, and then react with water to produce the compound represented by formula (I) or a pharmacologically acceptable salt thereof.
步骤11中的酸优选无机酸,且更优选盐酸。The acid in step 11 is preferably an inorganic acid, and more preferably hydrochloric acid.
步骤11反应温度优选-10~70℃,且优选0~50℃。The reaction temperature in step 11 is preferably -10 to 70°C, and preferably 0 to 50°C.
步骤11反应时间优选10分钟至24小时,且更优选10分钟至5小时。The step 11 reaction time is preferably 10 minutes to 24 hours, and more preferably 10 minutes to 5 hours.
化合物13和化合物14可以通过现有技术中的制备方法制得;也可以通过如下路线制得:Compound 13 and compound 14 can be prepared by the preparation methods in the prior art; they can also be prepared by the following route:
Figure PCTCN2020120751-appb-000009
Figure PCTCN2020120751-appb-000009
本发明的有益效果:The beneficial effects of the present invention:
采用CN101679339A制备化合物3时需要加入浓硫酸,不适合工业化生产,研究人员发现采用TMSOTf可以较好的反应,并且后处理容易,不会产生工业化污染。The use of CN101679339A to prepare compound 3 requires the addition of concentrated sulfuric acid, which is not suitable for industrial production. Researchers have found that the use of TMSOTf can react better, and the post-treatment is easy, and industrial pollution will not occur.
本发明创新性地采用一锅法由化合物(4)合成辛酸拉尼米韦中间体化合物(5),反应温和快速,并且产物无需柱层析,简单后处理即可进行下一步反应,节省能耗,减少污染,操作简单,成本低,适合工业化生产。The present invention innovatively adopts a one-pot method to synthesize lanimivir octoate intermediate compound (5) from compound (4). The reaction is mild and fast, and the product does not require column chromatography, and simple post-treatment can proceed to the next reaction, saving energy Consumption, pollution reduction, simple operation, low cost, suitable for industrial production.
本发明采用一锅法制备得到的辛酸拉尼米韦中间体化合物(5),收率高达87%以上,并且利用该中间体制得辛酸拉尼米韦的收率在85%以上。而采用CN101679339A的方法产物杂质较多,需要柱层析,的两步法的产率仅为76.9%。The lanimivir octoate intermediate compound (5) prepared by the one-pot method in the present invention has a yield of more than 87%, and the yield of lanimivir octoate prepared by using the intermediate is more than 85%. However, the product of the CN101679339A method has many impurities and requires column chromatography, and the yield of the two-step method is only 76.9%.
附图说明Description of the drawings
图1为化合物(2)的氢谱图;Figure 1 is a hydrogen spectrum of compound (2);
图2为化合物(3)的氢谱图;Figure 2 is a hydrogen spectrum of compound (3);
图3为化合物(4)的氢谱图;Figure 3 is a hydrogen spectrum of compound (4);
图4为化合物(5)的氢谱图;Figure 4 is a hydrogen spectrum of compound (5);
图5为化合物(6)的氢谱图;Figure 5 is a hydrogen spectrum of compound (6);
图6为化合物(12)的氢谱图;Figure 6 is a hydrogen spectrum of compound (12);
图7为化合物(13)的氢谱图。Figure 7 is a hydrogen spectrum of compound (13).
具体实施方式detailed description
本发明一锅法制备辛酸拉尼米韦中间体的方法,采用包括如下的合成方法:The one-pot method for preparing the lanimivir caprylate intermediate of the present invention adopts the following synthetic methods:
Figure PCTCN2020120751-appb-000010
Figure PCTCN2020120751-appb-000010
其中,R 1为苄基、取代苄基或烯丙基。 Wherein, R 1 is a benzyl group, a substituted benzyl group, or an allyl group.
上述取代苄基,指:苄基上的苯环被氯、溴、碘、硝基、烷氧基、烷基、芳香基等基团单取代或多取代。The aforementioned substituted benzyl group means that the benzene ring on the benzyl group is mono- or multiple-substituted by groups such as chlorine, bromine, iodine, nitro, alkoxy, alkyl, and aromatic.
上述一锅法制备辛酸拉尼米韦中间体的方法,包括以下步骤:将式(4)所示化合物与有机溶剂、R 1OH混合搅拌,之后在氮气保护下,加入NaH搅拌30~60min,然后加入(R 1O) 2CO,于0~80℃搅拌反应30min~24h,之后分离,得式(5)所示化合物。 The above-mentioned one-pot method for preparing lanimivir octoate intermediate includes the following steps: mixing and stirring the compound represented by formula (4) with an organic solvent and R 1 OH, and then adding NaH and stirring for 30-60 min under the protection of nitrogen. Then (R 1 O) 2 CO is added, and the reaction is stirred at 0-80° C. for 30 min-24 h, and then separated to obtain the compound represented by formula (5).
式(5)化合物粗品经甲苯或甲醇结晶,可得式(5)表示化合物的晶体。The crude compound of formula (5) is crystallized by toluene or methanol to obtain crystals of the compound represented by formula (5).
优选的,所述反应温度为10~60℃。Preferably, the reaction temperature is 10-60°C.
进一步优选的,所述反应温度为50~55℃。More preferably, the reaction temperature is 50-55°C.
优选的,所述反应时间为30min~5h。Preferably, the reaction time is 30 minutes to 5 hours.
所述有机溶剂为甲苯、N,N-二甲基甲酰胺、苯甲醇、正庚烷、甲基叔丁基醚、四氢呋喃、1,4-二氧六环中的任意一种或几种。The organic solvent is any one or more of toluene, N,N-dimethylformamide, benzyl alcohol, n-heptane, methyl tert-butyl ether, tetrahydrofuran, and 1,4-dioxane.
所述NaH的质量浓度为60%。The mass concentration of the NaH is 60%.
优选的,R 1为苄基。 Preferably, R 1 is benzyl.
上述方法中,式(4)所示化合物、R 1OH、NaH、(R 1O) 2CO的质量比为8-12:15-30:0.02-0.1:12-36。优选地,式(4)所示化合物、R 1OH、NaH、(R 1O) 2CO的质量比为9.8:20:0.04:24.22。 In the above method, the mass ratio of the compound represented by formula (4), R 1 OH, NaH, and (R 1 O) 2 CO is 8-12:15-30:0.02-0.1:12-36. Preferably, the mass ratio of the compound represented by formula (4), R 1 OH, NaH, and (R 1 O) 2 CO is 9.8:20:0.04:24.22.
上述式(4)所示化合物由以下路线合成:The compound represented by the above formula (4) is synthesized by the following route:
Figure PCTCN2020120751-appb-000011
Figure PCTCN2020120751-appb-000011
其中,R 1为苄基、取代苄基或烯丙基,X为Cl -、Br -、I -、MeSO 4 -、TfO -Wherein, R 1 is benzyl, substituted benzyl or allyl, X is Cl -, Br -, I - , MeSO 4 -, TfO -.
步骤1,在碱存在下,式(1)所示的化合物与R 1X反应生成式(2)表示的化合物。 Step 1. In the presence of a base, the compound represented by formula (1) reacts with R 1 X to produce the compound represented by formula (2).
所述碱没有特别的限制,可以与羧酸中和即可,可以是有机碱或无机碱。The base is not particularly limited, as long as it can be neutralized with a carboxylic acid, and it may be an organic base or an inorganic base.
优选的,所述有机碱诸如三乙胺、二异丙基乙胺、N,N-二甲基-4-氨基吡啶或吡啶;无机碱诸如碳酸铯、碳酸钾、碳酸钠、氢氧化钠、氢氧化钾。Preferably, the organic base such as triethylamine, diisopropylethylamine, N,N-dimethyl-4-aminopyridine or pyridine; inorganic base such as cesium carbonate, potassium carbonate, sodium carbonate, sodium hydroxide, Potassium hydroxide.
优选无机碱,且进一步优选碳酸铯或碳酸钾。An inorganic base is preferable, and cesium carbonate or potassium carbonate is more preferable.
步骤2,在有机碱存在下,式(2)表示的化合物与乙酸酐反应,生成式(3)表示的化合物。关于有机碱没有限制,可以与羧酸中和即可。Step 2. In the presence of an organic base, the compound represented by formula (2) reacts with acetic anhydride to produce the compound represented by formula (3). There is no restriction on the organic base, as long as it can be neutralized with a carboxylic acid.
优选的,所述有机碱为三乙胺、二异丙基乙胺、N,N-二甲基-4-氨基吡啶、吡啶中的任意一种或几种。Preferably, the organic base is any one or more of triethylamine, diisopropylethylamine, N,N-dimethyl-4-aminopyridine, and pyridine.
步骤2的反应温度为-30℃~100℃。优选为0~35℃。The reaction temperature in step 2 is -30°C to 100°C. Preferably it is 0-35 degreeC.
步骤2的反应时间是30min~24h。优选为10~15h。The reaction time of step 2 is 30min-24h. Preferably it is 10-15h.
步骤3,式(3)表示的化合物在三氟甲磺酸三甲硅酯催化下,产生式(4)表示的化合物。Step 3. The compound represented by formula (3) is catalyzed by trimethylsilyl trifluoromethanesulfonate to produce the compound represented by formula (4).
步骤3的反应温度0~70℃。优选为30℃~60℃。The reaction temperature in step 3 is 0 to 70°C. Preferably it is 30 degreeC-60 degreeC.
步骤3的反应时间是1.0h~24h。优选为1.0~3.0h。The reaction time of step 3 is 1.0h-24h. Preferably it is 1.0-3.0h.
步骤3后处理滴加三乙胺淬灭反应。After step 3, triethylamine was added dropwise to quench the reaction.
本发明辛酸拉尼米韦(式Ⅰ化合物)的制备方法,采用包括如下的合成方法:The preparation method of lanimivir octoate (compound of formula I) of the present invention adopts a synthetic method including the following:
Figure PCTCN2020120751-appb-000012
Figure PCTCN2020120751-appb-000012
步骤5是在碱存在下,式(5)表示的化合物与硫酸二甲酯或碘甲烷反应,产生式(6)表示的化合物。Step 5 is to react the compound represented by formula (5) with dimethyl sulfate or methyl iodide in the presence of a base to produce the compound represented by formula (6).
步骤5反应温度为0-70℃,优选0-30℃。The reaction temperature in step 5 is 0-70°C, preferably 0-30°C.
步骤5反应时间为30min~24h,优选1.0~15h。Step 5: The reaction time is 30 minutes to 24 hours, preferably 1.0 to 15 hours.
步骤6是在异丙醇钛催化下使式(6)表示的化合物与叠氮三甲基硅烷反应,以产生式(7)表示的化合物。Step 6 is to react the compound represented by formula (6) with azidotrimethylsilane under the catalysis of titanium isopropoxide to produce the compound represented by formula (7).
步骤6反应温度为0~120℃,优选为0~40℃。Step 6: The reaction temperature is 0 to 120°C, preferably 0 to 40°C.
步骤6反应时间为3.0~48h,优选3.0~24h。Step 6: The reaction time is 3.0 to 48 hours, preferably 3.0 to 24 hours.
步骤7是式(7)表示的化合物与三苯基膦反应以产生式(8)表示的化合物。Step 7 is the reaction of the compound represented by formula (7) with triphenylphosphine to produce the compound represented by formula (8).
步骤7反应温度为-10~80℃,优选0~60℃。The reaction temperature in step 7 is -10 to 80°C, preferably 0 to 60°C.
步骤7反应时间为10分钟~48h,优选10min~5h。Step 7: The reaction time is 10 minutes to 48 hours, preferably 10 minutes to 5 hours.
步骤8是式(8)表示的化合物与碱反应以产生式(9)表示的化合物。Step 8 is the reaction of the compound represented by formula (8) with a base to produce the compound represented by formula (9).
关于碱,优选无机碱,且更优选氢氧化锂、氢氧化钠、氢氧化钾。Regarding the base, inorganic bases are preferred, and lithium hydroxide, sodium hydroxide, and potassium hydroxide are more preferred.
步骤8反应温度优选-10~100℃,进一步优选0~50℃。The reaction temperature in step 8 is preferably -10 to 100°C, more preferably 0 to 50°C.
步骤8反应时间优选10分钟~48h,进一步优选0.5h~6h。Step 8: The reaction time is preferably 10 minutes to 48 hours, more preferably 0.5 hours to 6 hours.
步骤9是式(9)表示的化合物与式(10)表示的化合物反应以产生式(11)表示的化合物。Step 9 is the reaction of the compound represented by formula (9) with the compound represented by formula (10) to produce the compound represented by formula (11).
步骤9反应溶剂优选纯化水。The step 9 reaction solvent is preferably purified water.
步骤9反应温度是0-100℃,且优选5~50℃。The reaction temperature in Step 9 is 0-100°C, and preferably 5-50°C.
步骤9反应时间是24h~72h,且优选24~60h。Step 9: The reaction time is 24h to 72h, and preferably 24 to 60h.
步骤10是式(11)表示的化合物在三氟乙酸存在下反应,以产生式(12)表示的化合物。Step 10 is the reaction of the compound represented by formula (11) in the presence of trifluoroacetic acid to produce the compound represented by formula (12).
步骤10反应温度是-20~100℃,且优选0~45℃。The reaction temperature in step 10 is -20 to 100°C, and preferably 0 to 45°C.
步骤10反应时间是0.5h~24h,且优选0.5~8h。The reaction time of step 10 is 0.5 to 24 hours, and preferably 0.5 to 8 hours.
步骤11是在酸存在下使式(12)表示的化合物与化合物13或化合物14反应,之后再与水反应,以产生由式(Ⅰ)表示的化合物或其药理学可接受的盐。Step 11 is to react the compound represented by formula (12) with compound 13 or compound 14 in the presence of an acid, and then react with water to produce the compound represented by formula (I) or a pharmacologically acceptable salt thereof.
步骤11中的酸优选无机酸,且更优选盐酸。The acid in step 11 is preferably an inorganic acid, and more preferably hydrochloric acid.
步骤11反应温度优选-10~70℃,且优选0~50℃。The reaction temperature in step 11 is preferably -10 to 70°C, and preferably 0 to 50°C.
步骤11反应时间优选10分钟至24小时,且更优选10分钟至5小时。The step 11 reaction time is preferably 10 minutes to 24 hours, and more preferably 10 minutes to 5 hours.
化合物13和化合物14可以通过现有技术中的制备方法制得;也可以通过如下路线制得:Compound 13 and compound 14 can be prepared by the preparation methods in the prior art; they can also be prepared by the following route:
Figure PCTCN2020120751-appb-000013
Figure PCTCN2020120751-appb-000013
实施例1Example 1
化合物(2)的制备包括以下步骤:The preparation of compound (2) includes the following steps:
常温,于500ml反应瓶中依次加入N-乙酰神经氨酸(化合物1)30.93g、Cs 2CO 3 16.30g、125ml DMF、BrBn 26.70g,磁力搅拌反应24h,待反应结束后,过滤,母液浓缩至干,加入300ml异丙醇,升温至70℃,热滤出去不溶物,滤液常温搅拌3-4h,过滤,滤饼用异丙醇淋洗,滤饼减压干燥恒重得化合物(2)白色粉末18.50g,收率46.25%。化合物(2)的氢谱图如图1所示。 At room temperature, add 30.93g of N-acetylneuraminic acid (compound 1), Cs 2 CO 3 16.30g, 125ml DMF, and BrBn 26.70g to a 500ml reaction flask, and react with magnetic stirring for 24h. After the reaction is over, filter and concentrate the mother liquor. To dryness, add 300ml isopropanol, heat to 70°C, heat to filter out the insoluble matter, stir the filtrate at room temperature for 3-4h, filter, rinse the filter cake with isopropanol, dry the filter cake under reduced pressure to obtain compound (2) White powder 18.50g, yield 46.25%. The hydrogen spectrum of compound (2) is shown in Figure 1.
在其它实施例中,化合物(2)的制备过程中,加入300ml异丙醇后,还可以升温至80℃或75℃,然后再热滤出去不溶物。In other embodiments, in the preparation process of compound (2), after adding 300 ml of isopropanol, the temperature can be increased to 80°C or 75°C, and then the insoluble matter can be filtered out by hot filtration.
实施例2Example 2
化合物(3)的制备包括以下步骤:The preparation of compound (3) includes the following steps:
常温,于250ml反应瓶中,依次加入吡啶约70ml、化合物(2)18.50g,加毕控温20~25℃范围内,滴加醋酸酐37.50g,之后,加入4-二甲氨基吡啶(DMAP)约0.2g,维持20~25℃,搅拌反应过夜,反应液倒入350ml纯化水与1850ml乙酸乙酯混合液中,加毕,静置分层,有机层依次用200ml*2 5.0%HCl水溶液萃洗、200ml*2饱和碳酸氢钠水溶液萃洗,之后有机层无水硫酸钠干燥,过滤,淋洗,减压浓缩至干得无色油状物30.02g,收率106.4%。经柱层析(正庚烷~正庚烷/乙酸乙酯=1/2)纯化,收集目标组分(展开剂:乙酸乙酯),减压浓缩干,得化合物(3)白色粉末14.50g。化合物(3)的氢谱图如图2所示。At room temperature, in a 250ml reaction flask, add about 70ml of pyridine, 18.50g of compound (2), add 37.50g of acetic anhydride, and then add 4-dimethylaminopyridine (DMAP ) About 0.2g, maintain at 20~25℃, stir and react overnight, pour the reaction solution into 350ml purified water and 1850ml ethyl acetate mixture, after the addition, let stand for layering, and the organic layer shall be 200ml*2 5.0% HCl aqueous solution in turn After extraction and washing with 200ml*2 saturated sodium bicarbonate aqueous solution, the organic layer was dried with anhydrous sodium sulfate, filtered, rinsed, and concentrated under reduced pressure to dryness to obtain 30.02 g of a colorless oil with a yield of 106.4%. Purify by column chromatography (n-heptane~n-heptane/ethyl acetate=1/2), collect the target components (developing solvent: ethyl acetate), and concentrate to dryness under reduced pressure to obtain 14.50g of white powder of compound (3) . The hydrogen spectrum of compound (3) is shown in Figure 2.
实施例3Example 3
化合物(4)的制备包括以下步骤:The preparation of compound (4) includes the following steps:
常温,N 2保护下,于1000ml反应瓶中,依次加入化合物(3)13.20g、乙酸乙酯265ml,搅拌溶解澄清,控温15~25℃,滴加TMSOTf 14.46g,滴加结束,控温50~55℃范围内,搅拌反应2h,然后控温0~5℃,滴加三乙胺11.0g,之后加入冰水100ml,搅拌10min,静置分层,有机层再用100ml+50ml纯化水萃洗两次,有机层无水硫酸钠干燥,过滤,淋洗,减 压浓缩至干,得无色油状物。柱层析纯化(正庚烷~正庚烷/乙酸乙酯=1/1~乙酸乙酯)收集目标组分,减压浓缩至干得化合物(4)无色油状物9.14g。化合物(4)的氢谱图如图3所示。 At room temperature, N 2 protection, to a 1000ml reaction flask were added the compound (3) 13.20g, 265ml of ethyl acetate, clarified and stirred to dissolve, temperature 15 ~ 25 ℃, dropwise TMSOTf 14.46g, dropping, temperature control In the range of 50~55℃, stir and react for 2h, then control the temperature at 0~5℃, add 11.0g of triethylamine dropwise, then add 100ml of ice water, stir for 10min, stand for separation, and then use 100ml+50ml purified water for the organic layer Extract and wash twice, dry the organic layer with anhydrous sodium sulfate, filter, rinse, and concentrate under reduced pressure to dryness to obtain a colorless oil. Purification by column chromatography (n-heptane ~ n-heptane/ethyl acetate = 1/1 ~ ethyl acetate) to collect the target components, and concentrate under reduced pressure to dryness to obtain 9.14 g of compound (4) as a colorless oily substance. The hydrogen spectrum of compound (4) is shown in Figure 3.
实施例4Example 4
化合物(5)的制备包括以下步骤:The preparation of compound (5) includes the following steps:
常温,于反应瓶中依次加入化合物(4)9.80g、甲苯40ml、苯甲醇(即R 1取苄基)20.0ml,加毕,室温搅拌,氮气保护,之后,加入60%NaH 0.04g,搅拌30min,加入碳酸二苄酯(即R 1取苄基)24.22g,于50℃搅拌反应1h,加入0.032mol冰乙酸淬灭反应,湿法上柱,二氯甲烷冲洗小极性杂质,二氯甲烷/甲醇=40/1,洗刷目标组分,减压浓缩干得化合物(5)类白色固体,6.85g,收率87.96%。该收率远远高于CN101679339A中两步法得化合物(5)的收率(76.9%)。化合物(5)的氢谱图如图4所示。 At room temperature, the reaction flask was added successively the compound (4) 9.80g, toluene 40ml, benzyl alcohol (i.e. R 1 taken benzyl) 20.0 mL, addition was completed, stirring at room temperature, nitrogen, after which was added 60% NaH 0.04g, stirring 30min, dibenzyl carbonate (i.e., R 1 taken benzyl) 24.22 g, IH reaction was stirred at 50 deg.] C, 0.032mol glacial acetic acid was added to quench the reaction, the wet column, rinsing small polar impurities with dichloromethane, dichloro Methane/methanol=40/1, scrub the target components, and concentrate to dry under reduced pressure to obtain compound (5) as a white solid, 6.85 g, with a yield of 87.96%. The yield is much higher than the yield (76.9%) of compound (5) obtained by the two-step method in CN101679339A. The hydrogen spectrum of compound (5) is shown in Fig. 4.
在其它化合物(5)的制备实施例中,加入碳酸二苄酯后于55℃搅拌反应2h。在其他的实施例中,搅拌反应温度还可以为10℃、52℃、60℃或80℃。搅拌反应时间可以在30min~24h内调整。改变上述反应温度或时间,化合物(5)的收率与实施例4基本相同。In the preparation example of other compound (5), after adding dibenzyl carbonate, the reaction was stirred at 55° C. for 2 h. In other embodiments, the stirring reaction temperature can also be 10°C, 52°C, 60°C, or 80°C. The stirring reaction time can be adjusted within 30min-24h. Changing the above reaction temperature or time, the yield of compound (5) is basically the same as that of Example 4.
在其它化合物(5)的制备实施例中,甲苯溶剂还可以被替换为N,N-二甲基甲酰胺、苯甲醇、正庚烷、甲基叔丁基醚、四氢呋喃、1,4-二氧六环中的任意一种或几种。In the preparation examples of other compounds (5), the toluene solvent can also be replaced with N,N-dimethylformamide, benzyl alcohol, n-heptane, methyl tert-butyl ether, tetrahydrofuran, 1,4-di Any one or more of oxane.
在其他的化合物(5)的制备实施例中,式(4)所示化合物、R 1OH、NaH、(R 1O) 2CO的质量比为8:30:0.02:36。 In other preparation examples of compound (5), the mass ratio of the compound represented by formula (4), R 1 OH, NaH, and (R 1 O) 2 CO is 8:30:0.02:36.
在其他的化合物(5)的制备实施例中,式(4)所示化合物、R 1OH、NaH、(R 1O) 2CO的质量比为12:15:0.1:12。 In other preparation examples of compound (5), the mass ratio of the compound represented by formula (4), R 1 OH, NaH, and (R 1 O) 2 CO is 12:15:0.1:12.
在其他实施例中,R1还可以为被氯、溴、碘、硝基、烷氧基、烷基或芳香基取代的苄基;甚至R1还可以为烯丙基。In other embodiments, R1 can also be benzyl substituted by chlorine, bromine, iodine, nitro, alkoxy, alkyl or aromatic; even R1 can also be allyl.
实施例5Example 5
化合物(6)的制备包括以下步骤:The preparation of compound (6) includes the following steps:
N 2保护下,于250ml反应瓶中,依次加入化合物(5)6.85g、THF 28ml、DMF 7ml,加毕,搅拌至溶解澄清,控温0-5℃范围内,分批次加入60%NaH 0.91g,加毕维持温度0-5℃,搅拌30min,加入硫酸二甲酯2.88g,维持温度搅拌反应过夜,之后加入甲苯100ml、冰乙酸1.06g淬灭反应,反应液用40ml*2 5.0%NaHCO 3水溶液萃洗2次,水层用70ml*2甲苯萃洗2次,合并所有甲苯层无水硫酸钠干燥,过滤,淋洗,浓缩至近干,柱层析纯化(二氯甲烷→二氯甲烷/甲醇20/1),得化合物(6)无色油状物8.0g。化合物(6)的氢谱图如图5 所示。 Under the protection of N 2 , add 6.85g of compound (5), 28ml of THF, and 7ml of DMF to a 250ml reaction flask in sequence. After the addition, stir until the dissolution is clear. The temperature is controlled within the range of 0-5℃, and 60% NaH is added in batches. 0.91g, after addition, maintain the temperature at 0-5°C, stir for 30min, add 2.88g of dimethyl sulfate, keep the temperature for the reaction overnight, then add 100ml of toluene and 1.06g of glacial acetic acid to quench the reaction. Use 40ml*2 5.0% for the reaction solution Extract and wash with NaHCO 3 aqueous solution twice, and wash the water layer with 70ml*2 toluene twice, combine all the toluene layers and dry with anhydrous sodium sulfate, filter, rinse, concentrate to near dryness, and purify by column chromatography (dichloromethane→dichloro Methane/methanol 20/1) to obtain 8.0 g of compound (6) as a colorless oil. The hydrogen spectrum of compound (6) is shown in Figure 5.
实施例6Example 6
化合物(7)的制备包括以下步骤:The preparation of compound (7) includes the following steps:
N 2保护下,室温,于100ml反应瓶中,依次加入化合物(6)7.10g、甲苯21ml、叔丁醇7ml,加毕,搅拌至溶解澄清,加入TMSN 3 4.10g、异丙醇钛1.55g,维持20~25℃搅拌反应24h,之后过滤,滤液抽干,10ml甲醇淋洗,油泵带干滤饼,得化合物(7)米白色固体5.76g,收率:72.6%。 Under the protection of N 2 and at room temperature, in a 100ml reaction flask, add compound (6) 7.10g, toluene 21ml, tert-butanol 7ml, after the addition, stir until the dissolution is clear, add TMSN 3 4.10g, titanium isopropoxide 1.55g , The reaction was stirred at 20-25°C for 24h, then filtered, the filtrate was drained, 10ml methanol was rinsed, and the oil pump had a dry filter cake to obtain 5.76g off-white solid of compound (7), yield: 72.6%.
实施例7Example 7
化合物(8)的制备包括以下步骤:The preparation of compound (8) includes the following steps:
常温,于100ml反应瓶,依次加入化合物(7)5.00g、四氢呋喃20ml,搅拌至溶清,加入三苯基膦3.24g,加毕升温至40~50℃,搅拌反应10min,TLC(DCM/ME=10/1),原料消失,降至室温,得化合物(8)反应液。At room temperature, add 5.00g of compound (7) and 20ml of tetrahydrofuran to a 100ml reaction flask, stir until it is clear, add 3.24g of triphenylphosphine, heat up to 40~50℃ after addition, stir and react for 10min, TLC (DCM/ME = 10/1), the raw materials disappeared, and the temperature was reduced to room temperature to obtain the compound (8) reaction solution.
实施例8Example 8
化合物(9)的制备包括以下步骤:The preparation of compound (9) includes the following steps:
于实施例7中化合物(8)的反应液中,加入纯化水12.5g、25%NaOH水溶液5.40g,控温40~45℃,搅拌反应2h,TLC(DCM/ME=10/1),原料消失,降至室温,静置分液,水层加入6ml THF萃洗一次,水层滴加约4ml浓盐酸,调PH=2~3,再用25%NaOH水溶液调pH=9~10,得化合物(9)反应液。In the reaction solution of compound (8) in Example 7, 12.5g of purified water and 5.40g of 25% NaOH aqueous solution were added, the temperature was controlled at 40~45℃, and the reaction was stirred for 2h. TLC (DCM/ME=10/1), raw material Disappear, drop to room temperature, stand for liquid separation, add 6ml THF to the water layer to extract and wash once, add about 4ml concentrated hydrochloric acid dropwise to the water layer, adjust PH=2~3, and then adjust pH=9~10 with 25% NaOH aqueous solution. Compound (9) reaction solution.
实施例9Example 9
化合物(11)的制备包括以下步骤:The preparation of compound (11) includes the following steps:
室温,于实施例8化合物(9)反应液中,加入甲醇30ml、N,N’-双(叔丁氧羰基)-1H-吡唑-1-甲脒(化合物10)3.82g,维持20~25℃搅拌反应48h,调pH=8.5~8.8,反应液浓缩至尽干,加入100ml乙酸乙酯减压浓缩带除甲醇,浓缩液用50ml*3乙酸乙酯萃洗3次,水层用约1.3g浓盐酸调PH=2~3,水层用50ml*3乙酸乙酯萃取,合并有机层浓缩干,得白色固体(化合物11)5.20g,收率85.1%。At room temperature, add 30ml of methanol and 3.82g of N,N'-bis(tert-butoxycarbonyl)-1H-pyrazole-1-carboxamidine (compound 10) to the reaction solution of compound (9) of Example 8, maintaining 20~ Stir the reaction at 25°C for 48h, adjust pH=8.5~8.8, concentrate the reaction solution to dryness, add 100ml ethyl acetate and concentrate under reduced pressure to remove methanol. The concentrated solution is extracted and washed with 50ml*3 ethyl acetate for 3 times, and the water layer is washed with about 1.3g concentrated hydrochloric acid adjusted PH=2~3, the water layer was extracted with 50ml*3 ethyl acetate, and the combined organic layers were concentrated to dryness to obtain 5.20g of white solid (compound 11) with a yield of 85.1%.
实施例10Example 10
化合物(12)的制备包括以下步骤:The preparation of compound (12) includes the following steps:
将实施例9的化合物(11)加入50ml二氯甲烷,加入5g三氟乙酸室温反应3h,减压浓缩至干,加入25ml纯化水,用10%氢氧化钠水溶液调至pH=6~8。加入50ml甲醇,常温搅拌析晶,过滤,滤饼甲醇淋洗,40℃减压干燥得化合物(12)白色粉末2.74g,收率70.62%。 化合物(12)的氢谱图如图7所示。The compound (11) of Example 9 was added to 50ml of dichloromethane, 5g of trifluoroacetic acid was added to react at room temperature for 3h, concentrated under reduced pressure to dryness, 25ml of purified water was added, and the pH was adjusted to pH=6-8 with a 10% aqueous sodium hydroxide solution. Add 50 ml of methanol, stir and crystallize at room temperature, filter, rinse the filter cake with methanol, and dry under reduced pressure at 40°C to obtain 2.74 g of compound (12) as a white powder with a yield of 70.62%. The hydrogen spectrum of compound (12) is shown in Fig. 7.
实施例11Example 11
常温,N 2保护下,与100ml反应瓶中,依次加入化合物(12)2.00g、甲醇10ml、3.54g化合物13,最后加入10.5ml HCl甲醇溶液(1N氯化氢甲醇溶液),加毕,体系澄清,维持20-25℃,搅拌反应1h,减压浓缩近干,加入20ml纯化水,用20ml*3乙酸乙酯萃洗三次,水层用饱和碳酸钠调pH=7,搅拌1h,之后,用饱和碳酸钠调pH=8.5~9.0,搅拌3h,用6N盐酸调pH=5~6,搅拌30min,过滤,滤饼纯化水淋洗,滤饼35℃,减压干燥至恒重,得化合物(I)白色粉末2.34g,收率85.6%,HPLC 99.84%。 At room temperature, under N 2, with 100ml reaction flask, were added the compound (12) 2.00g, methanol 10ml, 3.54g compound 13, and finally methanol was added 10.5ml HCl (1N methanolic hydrogen chloride solution), the addition, to clarify the system, Keep at 20-25℃, stir and react for 1h, concentrate under reduced pressure to nearly dryness, add 20ml purified water, extract and wash with 20ml*3 ethyl acetate three times, adjust the pH to 7 with saturated sodium carbonate, stir for 1h, and then saturate it with Adjust pH=8.5~9.0 with sodium carbonate, stir for 3h, adjust pH=5~6 with 6N hydrochloric acid, stir for 30min, filter, filter cake purified water rinse, filter cake 35℃, dry under reduced pressure to constant weight to obtain compound (I ) White powder 2.34g, yield 85.6%, HPLC 99.84%.
本实施例中的化合物13可以替换为化合物14,其它条件不变。Compound 13 in this example can be replaced with compound 14, and other conditions remain unchanged.
对比例1Comparative example 1
该对比例与实施例4的区别仅在于,将碳酸二苄酯替换为羰基二咪唑。产物杂质较多,需要柱层析,最终得到的化合物(5)的收率仅为20%。This comparative example is different from Example 4 only in that dibenzyl carbonate is replaced with carbonyl diimidazole. The product has many impurities and requires column chromatography, and the final yield of compound (5) is only 20%.
对比例2Comparative example 2
该对比例与实施例4的区别仅在于,将碳酸二苄酯替换为氯甲酸苄酯。杂质较多,需要柱层析,最终得到的化合物(5)的收率仅为25%。This comparative example is different from Example 4 only in that dibenzyl carbonate is replaced with benzyl chloroformate. There are many impurities and column chromatography is required. The final yield of compound (5) is only 25%.
对本领域的技术人员来说,可根据以上描述的技术方案以及构思,做出其它各种相应的改变以及形变,而所有的这些改变以及形变都应该属于本发明权利要求的保护范围之内。For those skilled in the art, various other corresponding changes and deformations can be made based on the technical solutions and concepts described above, and all these changes and deformations should fall within the protection scope of the claims of the present invention.

Claims (10)

  1. 一种一锅法制备辛酸拉尼米韦中间体的方法,其特征在于,采用包括如下的合成方法:A one-pot method for preparing lanimivir octoate intermediates, which is characterized in that a synthesis method including the following is adopted:
    Figure PCTCN2020120751-appb-100001
    Figure PCTCN2020120751-appb-100001
    其中,R 1为苄基、取代苄基或烯丙基。 Wherein, R 1 is a benzyl group, a substituted benzyl group, or an allyl group.
  2. 根据权利要求1所述的方法,其特征在于,包括以下步骤:将式(4)所示化合物与有机溶剂、R 1OH混合搅拌,之后在氮气保护下,加入NaH搅拌30~60min,然后加入(R 1O) 2CO,于0~80℃搅拌反应30min~24h,之后分离,得式(5)所示化合物。 The method according to claim 1, characterized in that it comprises the following steps: mixing and stirring the compound represented by formula (4) with an organic solvent and R 1 OH, and then under the protection of nitrogen, adding NaH and stirring for 30-60 min, and then adding (R 1 O) 2 CO, stirred and reacted at 0~80°C for 30min~24h, and then separated to obtain the compound represented by formula (5).
  3. 根据权利要求2所述的方法,其特征在于,所述反应温度为10~60℃。The method according to claim 2, wherein the reaction temperature is 10-60°C.
  4. 根据权利要求3所述的方法,其特征在于,所述反应温度为50~55℃。The method of claim 3, wherein the reaction temperature is 50-55°C.
  5. 根据权利要求2所述的方法,其特征在于,所述反应时间为30min~5h。The method according to claim 2, wherein the reaction time is 30 minutes to 5 hours.
  6. 根据权利要求2所述的方法,其特征在于,所述有机溶剂为甲苯、N,N-二甲基甲酰胺、苯甲醇、正庚烷、甲基叔丁基醚、四氢呋喃、1,4-二氧六环中的任意一种或几种。The method according to claim 2, wherein the organic solvent is toluene, N,N-dimethylformamide, benzyl alcohol, n-heptane, methyl tert-butyl ether, tetrahydrofuran, 1,4- Any one or more of dioxane.
  7. 根据权利要求1所述的方法,其特征在于,所述NaH的质量浓度为60%。The method according to claim 1, wherein the mass concentration of the NaH is 60%.
  8. 根据权利要求1-7任一项所述的方法,其特征在于,R 1为苄基。 The method according to any one of claims 1-7, wherein R 1 is benzyl.
  9. 根据权利要求1所述的方法,其特征在于,式(4)所示化合物、R 1OH、NaH、(R 1O) 2CO的质量比为8-12:15-30:0.02-0.1:12-36。 The method according to claim 1, wherein the mass ratio of the compound represented by formula (4), R 1 OH, NaH, and (R 1 O) 2 CO is 8-12: 15-30: 0.02-0.1: 12-36.
  10. 根据权利要求9所述的方法,其特征在于,式(4)所示化合物、R 1OH、NaH、(R 1O) 2CO的质量比为9.8:20:0.04:24.22。 The method according to claim 9, wherein the mass ratio of the compound represented by formula (4), R 1 OH, NaH, and (R 1 O) 2 CO is 9.8:20:0.04:24.22.
PCT/CN2020/120751 2020-06-12 2020-10-14 Method for preparing laninamivir octanoate intermediate by means of one-pot synthesis WO2021248764A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202010532321.1A CN113801138A (en) 2020-06-12 2020-06-12 Method for preparing lanimivir octanoate intermediate by one-pot method
CN202010532321.1 2020-06-12

Publications (1)

Publication Number Publication Date
WO2021248764A1 true WO2021248764A1 (en) 2021-12-16

Family

ID=78846846

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2020/120751 WO2021248764A1 (en) 2020-06-12 2020-10-14 Method for preparing laninamivir octanoate intermediate by means of one-pot synthesis

Country Status (2)

Country Link
CN (1) CN113801138A (en)
WO (1) WO2021248764A1 (en)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101679339A (en) * 2007-04-11 2010-03-24 第一三共株式会社 Method for manufacturing neuraminic acid derivatives
CN102532080A (en) * 2010-12-29 2012-07-04 中国科学院上海药物研究所 Novel sialic acid derivant, preparation method thereof, drug composite comprising the same and application thereof
CN103435582A (en) * 2013-06-28 2013-12-11 深圳海王药业有限公司 Laninamivir octanoate preparation method
CN103974945A (en) * 2011-12-16 2014-08-06 第一三共株式会社 Method for producing neuraminic acid derivative
CN105085455A (en) * 2014-05-13 2015-11-25 中国科学院广州生物医药与健康研究院 Sialic acid analogues or pharmaceutically acceptable salts and application thereof
WO2020051498A1 (en) * 2018-09-06 2020-03-12 Cidara Therapeutics, Inc. Compositions and methods for the treatment of viral infections

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101679339A (en) * 2007-04-11 2010-03-24 第一三共株式会社 Method for manufacturing neuraminic acid derivatives
CN102532080A (en) * 2010-12-29 2012-07-04 中国科学院上海药物研究所 Novel sialic acid derivant, preparation method thereof, drug composite comprising the same and application thereof
CN103974945A (en) * 2011-12-16 2014-08-06 第一三共株式会社 Method for producing neuraminic acid derivative
CN103435582A (en) * 2013-06-28 2013-12-11 深圳海王药业有限公司 Laninamivir octanoate preparation method
CN105085455A (en) * 2014-05-13 2015-11-25 中国科学院广州生物医药与健康研究院 Sialic acid analogues or pharmaceutically acceptable salts and application thereof
WO2020051498A1 (en) * 2018-09-06 2020-03-12 Cidara Therapeutics, Inc. Compositions and methods for the treatment of viral infections

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FENG E. G. ET AL.: "Improved synthesis of laninamivir octanoate", CHINESE JOURNAL OF MEDICINAL CHEMISTRY, vol. 22, no. 4, 31 August 2012 (2012-08-31), pages 294 - 301, XP009186398, ISSN: 1005-0108 *

Also Published As

Publication number Publication date
CN113801138A (en) 2021-12-17

Similar Documents

Publication Publication Date Title
CN111233930B (en) Preparation method of Reidesciclovir
US10934257B2 (en) Method for preparing pimavanserin and tartrate thereof by using triphosgene
CN111116656A (en) Preparation method of Reidesciclovir
CN108794397A (en) A kind of his synthetic methods and its midbody compound of Luo Shasi
WO2016145990A1 (en) Method of preparation for ledipasvir and derivative thereof, and intermediate compound for preparation of ledipasvir
CN103570696A (en) Method for preparing intermediate of axitinib and application of intermediate in preparation of axitinib
WO2020052179A1 (en) Preparation process for amantadine nitrate derivative
WO2021248764A1 (en) Method for preparing laninamivir octanoate intermediate by means of one-pot synthesis
CN112047915B (en) Novel preparation process of C-glycoside derivatives
CN103145636B (en) 1,4-diacyl-3,6-diphenyl-1,4-dihydrotetrazine compound as well as preparation method and application thereof
WO2021248763A1 (en) Method for preparing laninamivir
CN111961114A (en) Argatroban intermediate and preparation method and application thereof
WO2023206607A1 (en) Method for preparing oxacephem parent nucleus intermediate
CN113667006B (en) Preparation method of cable Ma Lutai dipeptide side chain
CN117402104A (en) Preparation method of chiral intermediate of atorvastatin
CN108299466B (en) Improved dolutegravir synthesis method
WO2020253533A1 (en) Synthesis method for 1-methyl-1h-indazole-6-carboxylic acid
CN107176940B (en) A kind of preparation method for block-regulations woods
CN111253405B (en) Preparation method of biapenem intermediate
CN116082361B (en) Method for preparing Marbalo Sha Wei intermediate and Marbalo Sha Wei
CN110746471B (en) Preparation method of fondaparinux sodium disaccharide intermediate
CN111233857B (en) Synthetic method for continuously producing pexidininib
CN112142802B (en) Preparation method of fondaparinux sodium
CN107325092B (en) Novel preparation process of azithromycin
CN116514786A (en) Preparation method of deuterated indazole triazine compound

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20939724

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20939724

Country of ref document: EP

Kind code of ref document: A1